CSRO Releases Physician Biosimilars Survey Results

The Coalition of State Rheumatology Organizations (CSRO), released findings of a national survey of rheumatologists that explored perceptions of biosimilar medicines. They survey revealed rheumatologists have concerns about the biosimilars approval process and overwhelmingly support clearer regulatory standards for these new therapies. Specifically, 75 percent of rheumatologists surveyed say the FDA should mandate that biosimilars have a different non-proprietary name than the innovator biologic medicine and more than 82 percent of respondents believe that the FDA approval standards for designating a biosimilar as “interchangeable” must be very rigorous to ensure patient safety. Read more.